Objective: To describe patient and ocular outcomes following initial treatment with external beam radiotherapy (EBT) in eyes with Reese-Ellsworth groupVb ret inoblastoma. Methods: Retrospective case series (from Janua...Objective: To describe patient and ocular outcomes following initial treatment with external beam radiotherapy (EBT) in eyes with Reese-Ellsworth groupVb ret inoblastoma. Methods: Retrospective case series (from January 1, 1979, to Februa ry 28, 2002). The Kaplan-Meier method was used to analyze survival (ocular and patient) and incidence (second cancer)-data. Results: Two hundred forty-three patients with 1 or more Reese-Ellsworth group Vb eyes were identified. Of 284 g roup Vb eyes, 63 (22.2%) initially received EBT, vs 172 (60.6%) that were init ially enucleated. Of the 63 radiated group Vb eyes, 31 (49.2%) had no further t umor growth, 26 (41.3%) developed a recurrence, and 8 (12.7%) developed a new tumor. Of the 63 radiated group Vb eyes, 33 (52.4%) developed ocular complicati ons. The ocular survival rate of radiated group Vb eyes was 81.4%at 1 year and 53.4%at 10 years. Twenty-eight radiated group Vb eyes survived to the last fol low-up with visual acuity information. Thirteen patients developed second cance rs, 11 in the field of radiation. The probability of developing a second cancer following initial EBT for group Vb disease in patients with bilateral disease wa s 29.7%by 10 years after diagnosis. Survival from second cancers in patients wi th bilateral disease initially receiving EBT for group Vb disease was 93.6%at 5 years and 52.6%at 181/4 years. No patient with unilateral disease developed a second cancer. Deaths due to metastatic retinoblastoma were uncommon. Conclusion s: To our knowledge, this is the first study focusing exclusively on group Vb ey es treated initially with EBT, most of which were salvaged with vision. Outcome data provided herein are clinically relevant when choosing treatment options for advanced intraocular retinoblastoma.展开更多
Objective: To describe the visual field defects in retinobl- astoma survivors and relate those defects to characteristics such as tumor siz e, tumor location, and treatment modality. Methods: Thirty-one patients treat...Objective: To describe the visual field defects in retinobl- astoma survivors and relate those defects to characteristics such as tumor siz e, tumor location, and treatment modality. Methods: Thirty-one patients treated for retinoblastoma were included in this study. Humphrey visual fields were det ermined in 33 eyes. Results: Twenty-seven patients (29 eyes, 68 tumors) had suf ficient diagnosis and treatment data available for further analysis. Twenty-six of the 27 patients had both absolute and relative visual field defects. Four ty pes of visual field defects were observed and correlated with location of the tu mor and therapy to the individual tumors: (1) no residual defect, (2) absolute s cotoma, (3) arcuate and sector scotoma, and (4) "pseudo"-visual field defects caused by relative enophthalmos resulting from radiation. Conclusions: Patients with retinoblastoma demonstrate a variety of long-term visual field defects af ter treatment for their intraocular disease. Characteristics that determine the size and type of defects are tumor size, tumor location, and treatment method.展开更多
文摘Objective: To describe patient and ocular outcomes following initial treatment with external beam radiotherapy (EBT) in eyes with Reese-Ellsworth groupVb ret inoblastoma. Methods: Retrospective case series (from January 1, 1979, to Februa ry 28, 2002). The Kaplan-Meier method was used to analyze survival (ocular and patient) and incidence (second cancer)-data. Results: Two hundred forty-three patients with 1 or more Reese-Ellsworth group Vb eyes were identified. Of 284 g roup Vb eyes, 63 (22.2%) initially received EBT, vs 172 (60.6%) that were init ially enucleated. Of the 63 radiated group Vb eyes, 31 (49.2%) had no further t umor growth, 26 (41.3%) developed a recurrence, and 8 (12.7%) developed a new tumor. Of the 63 radiated group Vb eyes, 33 (52.4%) developed ocular complicati ons. The ocular survival rate of radiated group Vb eyes was 81.4%at 1 year and 53.4%at 10 years. Twenty-eight radiated group Vb eyes survived to the last fol low-up with visual acuity information. Thirteen patients developed second cance rs, 11 in the field of radiation. The probability of developing a second cancer following initial EBT for group Vb disease in patients with bilateral disease wa s 29.7%by 10 years after diagnosis. Survival from second cancers in patients wi th bilateral disease initially receiving EBT for group Vb disease was 93.6%at 5 years and 52.6%at 181/4 years. No patient with unilateral disease developed a second cancer. Deaths due to metastatic retinoblastoma were uncommon. Conclusion s: To our knowledge, this is the first study focusing exclusively on group Vb ey es treated initially with EBT, most of which were salvaged with vision. Outcome data provided herein are clinically relevant when choosing treatment options for advanced intraocular retinoblastoma.
文摘Objective: To describe the visual field defects in retinobl- astoma survivors and relate those defects to characteristics such as tumor siz e, tumor location, and treatment modality. Methods: Thirty-one patients treated for retinoblastoma were included in this study. Humphrey visual fields were det ermined in 33 eyes. Results: Twenty-seven patients (29 eyes, 68 tumors) had suf ficient diagnosis and treatment data available for further analysis. Twenty-six of the 27 patients had both absolute and relative visual field defects. Four ty pes of visual field defects were observed and correlated with location of the tu mor and therapy to the individual tumors: (1) no residual defect, (2) absolute s cotoma, (3) arcuate and sector scotoma, and (4) "pseudo"-visual field defects caused by relative enophthalmos resulting from radiation. Conclusions: Patients with retinoblastoma demonstrate a variety of long-term visual field defects af ter treatment for their intraocular disease. Characteristics that determine the size and type of defects are tumor size, tumor location, and treatment method.
